Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Plasma cell 1Genitourinary 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 1702Glioblastoma 1308Glioma 995Neuroblastoma 408Central Nervous System Neoplasms 384Astrocytoma 384Gliosarcoma 286Oligodendroglioma 238Neoplasms 226Breast Neoplasms 216Meningioma 179Medulloblastoma 172Carcinoma, Non-Small-Cell Lung 149Recurrence 147Neoplasm Metastasis 138Lung Neoplasms 138Ependymoma 128Melanoma 119Sarcoma 117Neurofibromatosis 1 110Meningeal Carcinomatosis 107Lymphoma 95Neuroma, Acoustic 82Diffuse Intrinsic Pontine Glioma 81Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Head and Neck Neoplasms 79Ovarian Neoplasms 73Lymphoma, Follicular 73Pheochromocytoma 71Paraganglioma 68

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Vascular Neoplasms × CNS × Clear all
NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
157 enrolled 26 charts
CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡